Literature DB >> 29294033

Improvements in Quality of Life: A New Indication for Treating Hepatitis C Virus Infection in Persons With Substance Use Disorders.

Ponni V Perumalswami1, Andrew H Talal2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29294033     DOI： 10.1093/infdis/jix682

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  3 in total

1.  Innovations in education: A prospective study of storytelling narratives to enhance hepatitis C virus knowledge among substance users.

Authors:  Andrew H Talal; Yu-Xin Ding; Marianthi Markatou
Journal:  World J Hepatol       Date:  2022-05-27

2.  Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis.

Authors:  David Back; Pamela Belperio; Mark Bondin; Francesco Negro; Andrew H Talal; Caroline Park; ZhenZhen Zhang; Brett Pinsky; Eric Crown; Federico J Mensa; Fiona Marra
Journal:  J Viral Hepat       Date:  2019-05-20       Impact factor: 3.728

3.  Utilizing patient perception of group treatment in exploring medication adherence, social support, and quality of life outcomes in people who inject drugs with hepatitis C.

Authors:  Kerry A Howard; Lior Rennert; Irene Pericot-Valverde; Moonseong Heo; Brianna L Norton; Matthew J Akiyama; Linda Agyemang; Alain H Litwin
Journal:  J Subst Abuse Treat       Date:  2021-05-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.